SequelSEC

BioNexus Gene Lab Corp BGLC

Services-Medical Laboratories · CIK 0001737523 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$3.13M
Fiscal year ended 2026-06-30
Operating income
-$2.56M
Fiscal year ended 2026-06-30
Free cash flow
-$853.60K
Fiscal year ended 2026-06-30

BioNexus Gene Lab Corp (BGLC) reported revenue of $3.13M and net income of -$2.58M for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from BioNexus Gene Lab Corp’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Services-Medical Laboratories.

Income

BioNexus Gene Lab Corp income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Revenue$3.13M
Cost of revenue$2.74M
Gross profit$385.89K
Operating income-$2.56M
Net income-$2.58M
Research & development$54.13K
Weighted-average diluted sharesUnavailable
Pretax income-$2.58M
Income tax expense$0
Diluted EPSUnavailable
Selling, general & administrative$1.93M
General & administrative$1.25M
Selling & marketing$675.96K

Balance

BioNexus Gene Lab Corp balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Cash & equivalents$1.23M
Total assets$8.73M
Current assets$4.94M
Total liabilities$947.98K
Current liabilities$812.94K
Total equity incl. NCI$7.78M
Temporary (mezzanine) equityUnavailable
Inventory$652.89K
Accounts receivable$15.54K
GoodwillUnavailable
Long-term debtUnavailable
Accounts payableUnavailable

Cash flow

BioNexus Gene Lab Corp cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Operating cash flow-$846.56K
Capital expenditures$7.04K
Investing cash flow$1.39M
Financing cash flow$374.05K
Net change in cash$854.76K
Stock-based compensationUnavailable
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortizationUnavailable

Derived

BioNexus Gene Lab Corp derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Free cash flow-$853.60K
Gross margin12.3%
Operating margin-81.8%
FCF margin-27.3%
SBC / revenueUnavailable
Current ratio6.08x
Revenue YoY growth-67.3%
Net margin-82.4%
R&D / revenue1.7%
CapEx / revenue0.2%
Long-term debt / equityUnavailable
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open BGLC in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-14View SEC filing
10-Q · Filed 2026-05-15View SEC filing
10-K · Filed 2026-04-14View SEC filing
10-Q · Filed 2025-11-14View SEC filing
10-Q · Filed 2025-08-18View SEC filing
10-Q · Filed 2025-05-15View SEC filing

Companies in the same industry

ACON ADVB AMS BDSX BLLN CAI CDNA CELC CFOR CSTL DGX FCHS

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.